Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Joe Copia who wrote (13650)	3/24/1999 7:59:00 AM
From: Wayne Rumball	Respond to of 25711

Wish I would have looked at it before the close. Bet you get yourself a quick 80% if you shorted.

To: Joe Copia who wrote (13650)	3/24/1999 9:28:00 AM
From: OFW	Read Replies (2) \| Respond to of 25711

Joe, any thoughts on WAST, good day yesterday and apparently involuntary bankruptcy is being dismissed. Could be strong turnaround play. Don't know the stock at all, any comments? Offie

To: Joe Copia who wrote (13650)	3/24/1999 9:29:00 AM
From: Blitz	Read Replies (2) \| Respond to of 25711

What do you think about this one Joe/Anyone? (BSNS WIRE) New Erectile Dysfunction Treatment Patent Granted to VIVUS New Erectile Dysfunction Treatment Patent Granted to VIVUS Business Editors/Health, Medical Writers MOUNTAIN VIEW, Calif.--(BW HealthWire)--March 24, 1999--VIVUS, Inc. (Nasdaq:VVUS) has been issued patent No. 5,886,039 for the "Method and Composition for Treating Erectile Dysfunction" by the U.S. Patent Office. This patent provides VIVUS with broad patent protection for the commercialization of ALIBRA(tm), VIVUS' second-generation transurethral treatment for male erectile dysfunction (ED). ALIBRA is the first transurethral two-drug combination therapy for the treatment of ED. The two drugs, alprostadil and prazosin, work by distinct and complementary mechanisms to initiate and maintain smooth muscle relaxation, the key physiological event required to achieve penile erection. Additional benefits of ALIBRA include a redesigned applicator and a single-strength dosage formulation. Because of these attributes, ALIBRA may become a welcome new prescribing option for primary care physicians and ED specialists. ALIBRA is currently in Phase III clinical trials and VIVUS plans to submit a New Drug Application for ALIBRA to the FDA during the fourth quarter of 1999. Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy for erectile dysfunction known as the transurethral system for erection. This therapy consists of a proprietary, non-invasive drug delivery system that delivers pharmacologic agents via the urethra. Note to editors and investors: Additional written materials, recent releases and Company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719). --30--rn/sf* CONTACT: VIVUS, Inc. Nina W. Ferrari, 650/934-5200 IR@VIVUS.com KEYWORD: CALIFORNIA INDUSTRY KEYWORD: MEDICINE PHARMACEUTICAL BIOTECHNOLOGY PRODUCT Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com * end of story *